Animal Vaccines Market Growth, Size and Share 2034
Animal Vaccines Market Growth, Size, Trends Analysis - By Animal Type, By Product, By Route of Administration, By Distribution Channel - Regional Outlook, Competitive Strategies and Segment Forecast to 2034
| Published: Sep-2025 | Report ID: HLCA25291 | Pages: 1 - 240 | Formats*: |
| Category : Healthcare | |||
Animal Vaccines Market Introduction and Overview
According to SPER Market Research, the Global Animal Vaccines Market is estimated to reach USD 34.53 billion by 2034 with a CAGR of 9.74%.
The report includes an in-depth analysis of the Global Animal Vaccines Market, including market size and trends, product mix, Applications, and supplier analysis. The global market for animal vaccines was valued at approximately USD 13.63 billion in 2024 and is projected to grow at a compound annual growth rate (CAGR) of 9.74% from 2025 to 2034. The rise in outbreaks of cattle diseases and the continuously increasing livestock population are significant factors driving the global acceptance of ruminant vaccines, particularly for cattle. Additionally, the surge in government initiatives plays a crucial role in facilitating market growth.
By Animal Type Insights:
In 2024, the livestock segment had the highest revenue share due to the increasing livestock population, government support, and disease outbreaks among cattle and sheep. Significant growth was noted in the raising of cattle, sheep, pigs, and poultry for meat. The companion animal segment is expected to grow rapidly as pets and certain animals like ferrets need vaccination against the canine distemper virus, for which no treatment is available after infection. Immunization is critical because distemper severely affects dogs and other animals, particularly those vulnerable to gastrointestinal infections.
By Product Insights:
The attenuated live vaccines segment was the largest revenue contributor in the animal vaccine market in 2024. Live attenuation is a traditional immunization method in veterinary medicine, valued for its low cost, strong immune responses, and long-lasting immunity, which makes it effective for a wide range of animals with smaller doses. The demand for these vaccines is expected to increase in the future. The recombinant vaccine segment is predicted to grow the fastest, as these vaccines help minimize the risk of disease after vaccination and can immunize against various virus strains. Recombinant vaccines are used for conditions such as canine distemper and avian influenza.
By Route of Administration Insights:
The subcutaneous injection route dominated the market, with sites behind the shoulder blades and neck being common for administering vaccines. This method is easier for training veterinary professionals, as it allows for slow drug absorption and is generally less painful for animals. Additionally, the intranasal vaccine segment is anticipated to grow swiftly due to its one-dose administration and effectiveness in stimulating immunity against respiratory diseases, which is crucial for livestock, poultry, and companion animals.
By Distribution Channel Insights:
The hospital and clinic pharmacy segment led the market in 2024, as these facilities adopt new technologies quickly and are primary sources for pet owners and farmers seeking animal healthcare. These entities often work closely with vaccine manufacturers, facilitating the introduction of new vaccines. E-commerce is expected to grow at the fastest rate, providing a wider reach for veterinarians and pet owners, especially in remote areas. Online platforms often have competitive prices, discounts, and bulk purchase options, encouraging increased sales.
Regional Insights:
North America led the market, capturing the largest share of revenue in 2024. This region is likely to maintain its dominant position throughout the predicted period. The substantial market share can be linked to the high incidence of livestock and zoonotic diseases, which result in significant animal mortality. Moreover, the market is projected to experience accelerated growth due to the presence of numerous well-established pharmaceutical companies that are actively seeking to broaden their global presence and commercialize their vaccine products. Furthermore, the increasing pet population in the United States and the rising incidence of canine diseases, which are driving higher vaccine adoption rates, are among the primary factors contributing to market growth.
Market Competitive Landscape:
The market is characterized by intense competition, featuring a mix of both small and large manufacturers of animal vaccines. Key elements impacting competitiveness are the rapid uptake of veterinary preventative injections and government-sponsored bulk vaccination purchasing. To maintain their market shares and diversify their product offerings, leading companies often pursue various strategies, including mergers and acquisitions, partnerships, and the introduction of new products.
Recent Developments:
Zoetis received a conditional license from the United States Department of Agriculture's Centre for Veterinary Biologics (CVB) in February 2025 for their Avian Influenza Vaccine, H5N2 Subtype, Killed Virus. This vaccination is specifically designed for use in hens. The conditional licence was granted based on the vaccine's established safety, purity, and reasonable expectation of efficacy, which were supported by serology evidence. Elanco Animal Health partnered with Medgene in February 2025 to commercialise a highly pathogenic avian influenza (HPAI) vaccine designed specifically for dairy cattle in the United States. This collaboration aims to address the cross-species transmission of HPAI, which has impacted approximately 1,000 dairy herds since March 2024. Vaxxilive Cocci 3, also known as Hatchpak Cocci III, is a poultry coccidiosis vaccine that was introduced by Boehringer Ingelheim in January 2024. The vaccination is used to protect birds from coccidiosis.
Scope of the report:
| Report Metric | Details |
| Market size available for years | 2021-2034 |
| Base year considered | 2024 |
| Forecast period | 2025-2034 |
| Segments covered | By Animal Type, By Product, By Route of Administration, By Distribution Channel |
| Regions covered | North America, Latin America, Asia-Pacific, Europe, and Middle East & Africa |
| Companies Covered | Zoetis, Merck & Co., Inc, Boehringer Ingelheim Animal Health, Elanco, Virba, Phibro Animal Health Corporation, Calier, Ceva, Bimeda Biologicals, Neogen Corporation. |
- Global Animal Vaccines Market Size (FY 2021-FY 2034)
- Overview of Global Animal Vaccines Market
- Segmentation of Global Animal Vaccines Market By Product (Attenuated Live Vaccines, Inactivated Vaccines, Subunit Vaccines, DNA Vaccines, Recombinant Vaccines)
- Segmentation of Global Animal Vaccines Market By Route of Administration (Subcutaneous, Intramuscular, Intranasal)
- Segmentation of Global Animal Vaccines Market By Animal Type (Livestock, Companion)
- Segmentation of Global Animal Vaccines Market By Distribution Channel (Retail, E-Commerce, Hospital/ Clinic Pharmacy)
- Statistical Snap of Global Animal Vaccines Market
- Expansion Analysis of Global Animal Vaccines Market
- Problems and Obstacles in Global Animal Vaccines Market
- Competitive Landscape in the Global Animal Vaccines Market
- Details on Current Investment in Global Animal Vaccines Market
- Competitive Analysis of Global Animal Vaccines Market
- Prominent Players in the Global Animal Vaccines Market
- SWOT Analysis of Global Animal Vaccines Market
- Global Animal Vaccines Market Future Outlook and Projections (FY 2025-FY 2034)
- Recommendations from Analyst
1. Introduction
- 1.1. Scope of the report
- 1.2. Market segment analysis
2. Research Methodology
- 2.1. Research data source
- 2.1.1. Secondary Data
- 2.1.2. Primary Data
- 2.1.3. SPERs internal database
- 2.1.4. Premium insight from KOL’s
- 2.2. Market size estimation
- 2.2.1. Top-down and Bottom-up approach
- 2.3. Data triangulation
3. Executive Summary
4. Market Dynamics
- 4.1. Driver, Restraint, Opportunity and Challenges analysis
- 4.1.1. Drivers
- 4.1.2. Restraints
- 4.1.3. Opportunities
- 4.1.4. Challenges
5. Market variable and outlook
- 5.1. SWOT Analysis
- 5.1.1. Strengths
- 5.1.2. Weaknesses
- 5.1.3. Opportunities
- 5.1.4. Threats
- 5.2. PESTEL Analysis
- 5.2.1. Political Landscape
- 5.2.2. Economic Landscape
- 5.2.3. Social Landscape
- 5.2.4. Technological Landscape
- 5.2.5. Environmental Landscape
- 5.2.6. Legal Landscape
- 5.3. PORTERs Five Forces
- 5.3.1. Bargaining power of suppliers
- 5.3.2. Bargaining power of buyers
- 5.3.3. Threat of Substitute
- 5.3.4. Threat of new entrant
- 5.3.5. Competitive rivalry
- 5.4. Heat Map Analysis
6. Competitive Landscape
- 6.1. Global Animal Vaccines Market Manufacturing Base Distribution, Sales Area, Product Type
- 6.2. Mergers & Acquisitions, Partnerships, Product Launch, and Collaboration in Global Animal Vaccines Market
7. Global Animal Vaccines Market, By Product (USD Million) 2021-2034
- 7.1. Attenuated Live Vaccines
- 7.2. Inactivated Vaccines
- 7.3. Subunit Vaccines
- 7.4. DNA Vaccines
- 7.5. Recombinant Vaccines
8. Global Animal Vaccines Market, By Route of Administration (USD Million) 2021-2034
- 8.1. Subcutaneous
- 8.2. Intramuscular
- 8.3. Intranasal
9. Global Animal Vaccines Market, By Animal Type (USD Million) 2021-2034
- 9.1. Livestock
- 9.1.1. Poultry
- 9.1.2. Aqua
- 9.1.3. Ruminants
- 9.1.4. Swine
- 9.2. Companion
- 9.2.1. Canine
- 9.2.2. Feline
- 9.2.3. Others
10. Global Animal Vaccines Market, By Distribution Channel (USD Million) 2021-2034
- 10.1. Retail
- 10.2. E-Commerce
- 10.3. Hospital/ Clinic Pharmacy
11. Global Animal Vaccines Market, (USD Million) 2021-2034
- 11.1. Global Animal Vaccines Market Size and Market Share
12. Global Animal Vaccines Market, By Region, (USD Million) 2021-2034
- 12.1. Asia-Pacific
- 12.1.1. Australia
- 12.1.2. China
- 12.1.3. India
- 12.1.4. Japan
- 12.1.5. South Korea
- 12.1.6. Rest of Asia-Pacific
- 12.2. Europe
- 12.2.1. France
- 12.2.2. Germany
- 12.2.3. Italy
- 12.2.4. Spain
- 12.2.5. United Kingdom
- 12.2.6. Rest of Europe
- 12.3. Middle East and Africa
- 12.3.1. Kingdom of Saudi Arabia
- 12.3.2. United Arab Emirates
- 12.3.3. Qatar
- 12.3.4. South Africa
- 12.3.5. Egypt
- 12.3.6. Morocco
- 12.3.7. Nigeria
- 12.3.8. Rest of Middle-East and Africa
- 12.4. North America
- 12.4.1. Canada
- 12.4.2. Mexico
- 12.4.3. United States
- 12.5. Latin America
- 12.5.1. Argentina
- 12.5.2. Brazil
- 12.5.3. Rest of Latin America
13. Company Profile
- 13.1. Zoetis
- 13.1.1. Company details
- 13.1.2. Financial outlook
- 13.1.3. Product summary
- 13.1.4. Recent developments
- 13.2. Merck & Co., Inc
- 13.2.1. Company details
- 13.2.2. Financial outlook
- 13.2.3. Product summary
- 13.2.4. Recent developments
- 13.3. Boehringer Ingelheim Animal Health
- 13.3.1. Company details
- 13.3.2. Financial outlook
- 13.3.3. Product summary
- 13.3.4. Recent developments
- 13.4. Elanco
- 13.4.1. Company details
- 13.4.2. Financial outlook
- 13.4.3. Product summary
- 13.4.4. Recent developments
- 13.5. Virbac
- 13.5.1. Company details
- 13.5.2. Financial outlook
- 13.5.3. Product summary
- 13.5.4. Recent developments
- 13.6. Phibro Animal Health Corporation
- 13.6.1. Company details
- 13.6.2. Financial outlook
- 13.6.3. Product summary
- 13.6.4. Recent developments
- 13.7. Calier
- 13.7.1. Company details
- 13.7.2. Financial outlook
- 13.7.3. Product summary
- 13.7.4. Recent developments
- 13.8. Ceva
- 13.8.1. Company details
- 13.8.2. Financial outlook
- 13.8.3. Product summary
- 13.8.4. Recent developments
- 13.9. Bimeda Biologicals
- 13.9.1. Company details
- 13.9.2. Financial outlook
- 13.9.3. Product summary
- 13.9.4. Recent developments
- 13.10. Neogen Corporation
- 13.10.1. Company details
- 13.10.2. Financial outlook
- 13.10.3. Product summary
- 13.10.4. Recent developments
- 13.11. Others
14. Conclusion
15. List of Abbreviations
16. Reference Links
SPER Market Research’s methodology uses great emphasis on primary research to ensure that the market intelligence insights are up to date, reliable and accurate. Primary interviews are done with players involved in each phase of a supply chain to analyze the market forecasting. The secondary research method is used to help you fully understand how the future markets and the spending patterns look likes.
The report is based on in-depth qualitative and quantitative analysis of the Product Market. The quantitative analysis involves the application of various projection and sampling techniques. The qualitative analysis involves primary interviews, surveys, and vendor briefings. The data gathered as a result of these processes are validated through experts opinion. Our research methodology entails an ideal mixture of primary and secondary initiatives.
Frequently Asked Questions About This Report
Animal Vaccines Market size is USD 34.53 billion from 2025 to 2034.
Animal Vaccines Market is covered By Animal Type, By Product, By Route of Administration, By Distribution Channel
The North America, Latin America, Asia-Pacific, Europe, and Middle East & Africa is the highest Market share in the Animal Vaccines Market.
Zoetis, Merck & Co., Inc, Boehringer Ingelheim Animal Health, Elanco, Virba, Phibro Animal Health Corporation, Calier, Ceva, Bimeda Biologicals, Neogen Corporation.
The report includes an in-depth analysis of the Global Animal Vaccines Market, including market size and trends, product mix, Applications, and supplier analysis.
Animal Vaccines Market is projected to reach USD 34.53 billion by 2034, growing at a CAGR of of 9.74% during the forecast period.
Animal Vaccines Market grew in Market size from 2025. The Market is expected to reach USD 34.53 billion by 2034, at a CAGR of 9.74% during the forecast period.
Animal Vaccines Market CAGR of 9.74% during the forecast period.
You can get the sample pages by clicking the link - Click Here
PLACE AN ORDER
Year End Discount
Sample Report
Pre-Purchase Inquiry
NEED CUSTOMIZATION?
Request CustomizationCALL OR EMAIL US
100% Secure Payment
Related Reports
Have a glance of the Report
Our Global Clients
Our data-driven insights have influenced the strategy of 200+ reputed companies across the globe.
